| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 13 | 2021 | 1226 | 1.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 12 | 2021 | 833 | 1.170 |
Why?
|
| Positron-Emission Tomography | 14 | 2019 | 2173 | 1.110 |
Why?
|
| Hodgkin Disease | 10 | 2022 | 1429 | 0.850 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2014 | 172 | 0.780 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2014 | 223 | 0.760 |
Why?
|
| Multimodal Imaging | 7 | 2019 | 550 | 0.650 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 408 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 7551 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.510 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 716 | 0.480 |
Why?
|
| Neurilemmoma | 1 | 2014 | 127 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2022 | 15862 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.420 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.420 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2021 | 1664 | 0.410 |
Why?
|
| Radiopharmaceuticals | 8 | 2020 | 1301 | 0.350 |
Why?
|
| Mediastinal Neoplasms | 3 | 2019 | 423 | 0.350 |
Why?
|
| Parathyroid Neoplasms | 2 | 2020 | 185 | 0.300 |
Why?
|
| Tumor Burden | 4 | 2019 | 1987 | 0.300 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 4971 | 0.210 |
Why?
|
| Rituximab | 5 | 2019 | 1528 | 0.210 |
Why?
|
| Parathyroid Glands | 2 | 2019 | 127 | 0.200 |
Why?
|
| Bone Neoplasms | 4 | 2020 | 2576 | 0.200 |
Why?
|
| Doxorubicin | 9 | 2019 | 3005 | 0.190 |
Why?
|
| Histiocytes | 1 | 2021 | 94 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.180 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2020 | 57 | 0.180 |
Why?
|
| Neoplasm, Residual | 3 | 2021 | 1656 | 0.180 |
Why?
|
| Young Adult | 14 | 2021 | 21445 | 0.180 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2019 | 37 | 0.180 |
Why?
|
| Sodium Fluoride | 1 | 2019 | 30 | 0.170 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 84 | 0.170 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2019 | 156 | 0.170 |
Why?
|
| Cushing Syndrome | 1 | 2019 | 70 | 0.170 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 133 | 0.160 |
Why?
|
| Whole Body Imaging | 1 | 2019 | 114 | 0.160 |
Why?
|
| Middle Aged | 21 | 2021 | 86204 | 0.160 |
Why?
|
| Glycolysis | 3 | 2019 | 519 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 191 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 895 | 0.160 |
Why?
|
| Adult | 21 | 2021 | 77950 | 0.160 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2019 | 135 | 0.150 |
Why?
|
| Arteries | 1 | 2019 | 274 | 0.150 |
Why?
|
| Fever | 1 | 2020 | 497 | 0.150 |
Why?
|
| Pheochromocytoma | 2 | 2010 | 281 | 0.150 |
Why?
|
| Humans | 39 | 2022 | 261506 | 0.140 |
Why?
|
| Aged | 18 | 2021 | 70117 | 0.140 |
Why?
|
| Male | 25 | 2021 | 123000 | 0.140 |
Why?
|
| Etoposide | 4 | 2019 | 870 | 0.130 |
Why?
|
| Calcinosis | 1 | 2019 | 423 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Vinblastine | 4 | 2018 | 453 | 0.130 |
Why?
|
| Retrospective Studies | 12 | 2022 | 37905 | 0.130 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 13658 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2018 | 514 | 0.130 |
Why?
|
| Bleomycin | 4 | 2018 | 467 | 0.130 |
Why?
|
| Female | 22 | 2021 | 141928 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2014 | 166 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8865 | 0.120 |
Why?
|
| Dacarbazine | 4 | 2018 | 485 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 125 | 0.120 |
Why?
|
| Adolescent | 9 | 2019 | 31252 | 0.120 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 406 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 634 | 0.110 |
Why?
|
| Vincristine | 4 | 2019 | 1511 | 0.110 |
Why?
|
| Lymphoma | 1 | 2021 | 1467 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2017 | 1824 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2016 | 769 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2011 | 111 | 0.090 |
Why?
|
| Models, Biological | 2 | 2018 | 3254 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 713 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2017 | 929 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1763 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2019 | 3001 | 0.090 |
Why?
|
| Prednisone | 3 | 2019 | 984 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 29902 | 0.080 |
Why?
|
| Phantoms, Imaging | 2 | 2011 | 1271 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2019 | 32848 | 0.080 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 37 | 0.080 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 489 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2010 | 213 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 402 | 0.080 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2019 | 121 | 0.080 |
Why?
|
| Paraganglioma | 1 | 2010 | 170 | 0.080 |
Why?
|
| Prognosis | 5 | 2020 | 21713 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 297 | 0.070 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2019 | 226 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2015 | 864 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1014 | 0.070 |
Why?
|
| Salvage Therapy | 3 | 2021 | 2054 | 0.070 |
Why?
|
| Mammography | 1 | 2011 | 1010 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 14889 | 0.060 |
Why?
|
| Disease Progression | 4 | 2019 | 6682 | 0.060 |
Why?
|
| Child | 3 | 2014 | 29154 | 0.060 |
Why?
|
| Recurrence | 3 | 2017 | 4758 | 0.060 |
Why?
|
| Glucose | 1 | 2010 | 1248 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 4744 | 0.060 |
Why?
|
| Survival Rate | 4 | 2018 | 12221 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2012 | 1330 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 5112 | 0.050 |
Why?
|
| Neoplasms | 2 | 2019 | 15193 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.050 |
Why?
|
| Neck | 2 | 2017 | 383 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 1972 | 0.050 |
Why?
|
| Antigens, Ly | 1 | 2000 | 49 | 0.050 |
Why?
|
| Hypertension | 1 | 2010 | 1503 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 1866 | 0.050 |
Why?
|
| Remission Induction | 2 | 2019 | 3569 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 202 | 0.040 |
Why?
|
| Neutropenia | 2 | 2015 | 968 | 0.040 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 60 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2015 | 1450 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2017 | 3842 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 4975 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2010 | 305 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8873 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10001 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2000 | 309 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2278 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 194 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.040 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 150 | 0.040 |
Why?
|
| Biological Transport | 1 | 2019 | 597 | 0.040 |
Why?
|
| Parathyroidectomy | 1 | 2019 | 203 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.040 |
Why?
|
| Mediastinum | 1 | 2019 | 268 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 500 | 0.030 |
Why?
|
| Epistaxis | 1 | 2015 | 30 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 130 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6207 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 756 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2000 | 904 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 452 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5319 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2014 | 246 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 619 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 899 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 7702 | 0.030 |
Why?
|
| Radiometry | 1 | 2019 | 980 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 315 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2021 | 12873 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Calcium | 1 | 2019 | 1537 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 1335 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 631 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2594 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 242 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 1008 | 0.030 |
Why?
|
| Diarrhea | 1 | 2015 | 686 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.030 |
Why?
|
| Alopecia | 1 | 2012 | 126 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2011 | 91 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 1914 | 0.020 |
Why?
|
| Metanephrine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Carney Complex | 1 | 2010 | 7 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2011 | 355 | 0.020 |
Why?
|
| Piperidines | 1 | 2015 | 1035 | 0.020 |
Why?
|
| Methotrexate | 1 | 2013 | 999 | 0.020 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2010 | 31 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2010 | 65 | 0.020 |
Why?
|
| Succinate Dehydrogenase | 1 | 2010 | 43 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 690 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 1391 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2012 | 304 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 11538 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 479 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2370 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 829 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 6550 | 0.020 |
Why?
|
| Cytarabine | 1 | 2013 | 1973 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 4307 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 1471 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 781 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 716 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 1351 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2012 | 717 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2015 | 3518 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 5159 | 0.010 |
Why?
|
| Receptors, NK Cell Lectin-Like | 1 | 2000 | 2 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2014 | 5270 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6009 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 4844 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17523 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2000 | 153 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 334 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 162 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 14551 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14289 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 675 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 1399 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 2314 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 1073 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 1555 | 0.010 |
Why?
|
| Animals | 2 | 2014 | 59536 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 4917 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4557 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 5114 | 0.010 |
Why?
|
| Gene Expression | 1 | 2000 | 3570 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 15179 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 4367 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 15694 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 34495 | 0.000 |
Why?
|